Logo image of LVTX

LAVA THERAPEUTICS NV (LVTX) Stock Fundamental Analysis

NASDAQ:LVTX - Nasdaq - NL0015000AG6 - Common Stock - Currency: USD

1.34  -0.03 (-2.19%)

Fundamental Rating

3

Taking everything into account, LVTX scores 3 out of 10 in our fundamental rating. LVTX was compared to 559 industry peers in the Biotechnology industry. LVTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LVTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year LVTX has reported negative net income.
In the past 5 years LVTX always reported negative net income.
In the past 5 years LVTX reported 4 times negative operating cash flow.
LVTX Yearly Net Income VS EBIT VS OCF VS FCFLVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

LVTX has a Return On Assets of -35.29%. This is in the better half of the industry: LVTX outperforms 61.54% of its industry peers.
LVTX has a Return On Equity (-97.40%) which is in line with its industry peers.
Industry RankSector Rank
ROA -35.29%
ROE -97.4%
ROIC N/A
ROA(3y)-31.44%
ROA(5y)-40.51%
ROE(3y)-69.63%
ROE(5y)-90.26%
ROIC(3y)N/A
ROIC(5y)N/A
LVTX Yearly ROA, ROE, ROICLVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Gross Margin of LVTX (100.00%) is better than 99.64% of its industry peers.
LVTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LVTX Yearly Profit, Operating, Gross MarginsLVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

LVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LVTX remains at a similar level compared to 1 year ago.
The number of shares outstanding for LVTX has been increased compared to 5 years ago.
Compared to 1 year ago, LVTX has a worse debt to assets ratio.
LVTX Yearly Shares OutstandingLVTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
LVTX Yearly Total Debt VS Total AssetsLVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -3.25, we must say that LVTX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.25, LVTX is in line with its industry, outperforming 47.76% of the companies in the same industry.
LVTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.25
ROIC/WACCN/A
WACC7.22%
LVTX Yearly LT Debt VS Equity VS FCFLVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 6.73 indicates that LVTX has no problem at all paying its short term obligations.
LVTX has a Current ratio of 6.73. This is in the better half of the industry: LVTX outperforms 64.94% of its industry peers.
LVTX has a Quick Ratio of 6.73. This indicates that LVTX is financially healthy and has no problem in meeting its short term obligations.
LVTX's Quick ratio of 6.73 is fine compared to the rest of the industry. LVTX outperforms 65.30% of its industry peers.
Industry RankSector Rank
Current Ratio 6.73
Quick Ratio 6.73
LVTX Yearly Current Assets VS Current LiabilitesLVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.70% over the past year.
LVTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 77.01%.
The Revenue has been growing by 33.82% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)3.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
Revenue 1Y (TTM)77.01%
Revenue growth 3Y33.82%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

LVTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.54% yearly.
LVTX is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y-45.32%
EPS Next 2Y8.89%
EPS Next 3Y15.92%
EPS Next 5Y11.54%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
LVTX Yearly Revenue VS EstimatesLVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2030 2031 2032 5M 10M 15M
LVTX Yearly EPS VS EstimatesLVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LVTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LVTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LVTX Price Earnings VS Forward Price EarningsLVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LVTX Per share dataLVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as LVTX's earnings are expected to grow with 15.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.89%
EPS Next 3Y15.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LVTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LAVA THERAPEUTICS NV

NASDAQ:LVTX (6/11/2025, 8:00:01 PM)

1.34

-0.03 (-2.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-18 2025-08-18
Inst Owners35.48%
Inst Owner Change24.26%
Ins Owners0.52%
Ins Owner Change0%
Market Cap35.26M
Analysts78
Price Target1.87 (39.55%)
Short Float %0.5%
Short Ratio1.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)60.08%
Min EPS beat(2)53.47%
Max EPS beat(2)66.68%
EPS beat(4)3
Avg EPS beat(4)24.77%
Min EPS beat(4)-36.66%
Max EPS beat(4)66.68%
EPS beat(8)6
Avg EPS beat(8)15.96%
EPS beat(12)10
Avg EPS beat(12)26.68%
EPS beat(16)14
Avg EPS beat(16)24.89%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-15.39%
EPS NQ rev (1m)21.41%
EPS NQ rev (3m)7.29%
EPS NY rev (1m)13.4%
EPS NY rev (3m)2.03%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.94
P/FCF N/A
P/OCF N/A
P/B 1.37
P/tB 1.37
EV/EBITDA N/A
EPS(TTM)-1.04
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.46
BVpS0.98
TBVpS0.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.29%
ROE -97.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM N/A
ROA(3y)-31.44%
ROA(5y)-40.51%
ROE(3y)-69.63%
ROE(5y)-90.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.73
Quick Ratio 6.73
Altman-Z -3.25
F-ScoreN/A
WACC7.22%
ROIC/WACCN/A
Cap/Depr(3y)66.67%
Cap/Depr(5y)88.88%
Cap/Sales(3y)4.68%
Cap/Sales(5y)8.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
EPS Next Y-45.32%
EPS Next 2Y8.89%
EPS Next 3Y15.92%
EPS Next 5Y11.54%
Revenue 1Y (TTM)77.01%
Revenue growth 3Y33.82%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y31.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.48%
OCF growth 3YN/A
OCF growth 5YN/A